A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors

GCAR1（一种嵌合抗原受体 (CAR) T 细胞疗法）针对复发/难治性表达 GPNMB 的实体瘤患者的 I 期可行性和安全性研究

• 批准号: 480122
• 负责人: Shafey Mona
• 金额: $ 203.69万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=480122&lang=en
• 关键词: Alveolar Soft Part Sarcoma; Car T; Immunotherapy; Renal Cell Carcinoma; Sarcoma; Triple-Negative Breast Cancer

CAR T-cell therapy is a promising new treatment that has been used successfully to treat and even cure refractory blood cancers. It involves taking functional T-cells from the patient, genetically modifying them to target the cancer cell, and then infusi

CAR T细胞疗法是一种有前途的新疗法，已成功用于治疗甚至治愈难治性血癌。 它包括从患者体内提取功能性T细胞，对它们进行基因修饰以靶向癌细胞，然后将其输注到患者体内。